News

The trial will evaluate the efficacy of PRX302 versus placebo using the optimal treatment volume established in the open-label Phase II study results announced in November, 2008. The

Under the terms of the merger agreement, Targanta shareholders will receive $2 in cash up front for each common share tendered, or approximately $42 million. Targanta shareholders may

This case was initiated by CoreValve in the UK in September 2007. In response, Edwards counter-sued, claiming infringement of the patent. While the court upheld Edwards’s patent, it

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in

The respiratory syncytial virus (RSV)-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus infection in adult

Elevate anterior prolapse repair system is a minimally invasive, single-incision total transvaginal approach for treating cystoceles and vault prolapse. It utilizes minimal blind needle passages and follows proven

The Phase III study is a US multi-center, randomized, controlled trial, in which the efficacy and safety of Trinam will be investigated in patients with end-stage renal disease

To date, the FDA has not approved any product for treating corneal graft rejection. Currently, EyeGate is enrolling two Phase II clinical studies utilizing EGP-437 in uveitis and

Liquidity and Capital Resources As of November 30, 2008, the company working capital deficit of $531,257 was comprised of current assets of $16,073 and current liabilities of $547,330.